1 active not recruiting, 1 recruiting, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Recurrent Ovarian Carcinosarcoma: new trials by email Literature Review of Recurrent Ovarian Carcinosarcoma trials Research Report on Recurrent Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2018-10-16 | 2025-04-17 |
Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Colorectal Neoplasms (1)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Ovarian Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Fallopian Tube Diseases (2)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Cyclophosphamide (2) · 4-toluenesulfonyl fluoride (1) · ASTX-660 (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Biopsy (1) · Blood Component Removal (1) · Disulfides (1) · Immunoglobulin G (1) · Interleukin-2 (1) · Leukapheresis (1) · Paclitaxel (1) · Taxes (1)
Mayo Clinic (2) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (3)
Amir A Jazaeri (1) · Brenda J. Ernst, M.D. (1) · Kristen P Zeligs (1) · Matthew S. Block, MD, PhD (1)
R01CA276313 (1), U10CA180868 (1)